Albumin Binding as a Strategy for Improving Tumor Targeting of Radiolabeled Compounds

Area of Science:

• Radiopharmaceutical chemistry
• Molecular imaging
• Cancer therapy

Background:

• Radiolabeled compounds target cancer receptors (SSTR2, PSMA, HER2).
• Rapid blood clearance of radiopharmaceuticals limits efficacy and tumor accumulation.
• Kidney clearance is a major factor in radiopharmaceutical circulation time.

Purpose of the Study:

• To review the impact of albumin-binding moieties on radiopharmaceutical pharmacokinetics.
• To evaluate various albumin-binding strategies for enhanced tumor targeting.
• To analyze effects on circulation time and tumor accumulation in preclinical and clinical studies.

Main Methods:

• Literature review of studies on radiolabeled compounds with albumin-binding moieties.
• Analysis of pharmacokinetic data from animal and human studies.
• Comparison of different albumin-binding groups (e.g., Evans blue, iodophenyl, palmitic acid, scaffold proteins).

Main Results:

• Albumin binding increases radiopharmaceutical molecule size, slowing kidney clearance.
• Incorporation of albumin-binding moieties lengthens in vivo biological half-life.
• Elevated tumor accumulation was observed, but with potential for increased background noise.

Conclusions:

• Albumin-binding moieties represent a viable strategy to improve radiopharmaceutical tumor uptake.
• Careful selection of albumin binders is crucial to balance efficacy and background signal.
• Further research is needed to optimize albumin-binding radiopharmaceuticals for clinical translation.